Dung Le

Dung Le was a key investigator in the landmark studies demonstrating that mismatch repair deficient tumors respond remarkably well to PD-1 checkpoint blockade, a finding that led to the first tumor-agnostic FDA approval of pembrolizumab. She has led clinical trials across MSI-H gastrointestinal malignancies and has contributed to understanding the immunological mechanisms underlying immunotherapy response in these tumors. Her work continues to refine which patients benefit most from immunotherapy and how to extend these benefits to MMR-proficient tumors. She is a recipient of multiple oncology leadership awards.